Safety and efficacy of Tranilast for the treatment of relapsed or resistant lymphoid tumors; a pilot study
Not Applicable
Recruiting
- Conditions
- relapsed or resistant lymphoid tumors
- Registration Number
- JPRN-UMIN000008210
- Lead Sponsor
- Tokyo Medical and Dental University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
Not provided
Exclusion Criteria
1, Allergy to Tranilast 2, Severe uncontrollable diabetes or infection 3, Active double cancers 4, Pregnant or lactating women or women of childbearing potential 5, AST,ALT>5xULN, T-Bil 3XULN 6, Cre>3xULN 7, Psychosis 8, Inadequate condition as diagnosed by primary physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety of 2 weeks administration of Tranilast for patients with lymphoid tumors
- Secondary Outcome Measures
Name Time Method